

Reproductive Factors and Exogenous Hormone Use in Relation to Risk of Glioma and Meningioma in a Large European Cohort Study

Dominique S. Michaud^{1,2}, Valentina Gallo¹, Brigitte Schlehofer³, Anne Tjønneland⁷, Anja Olsen⁷, Kim Overvad⁵, Christina C. Dahm^{5,6}, Rudolf Kaaks⁴, Annekatrin Lukanova⁴, Heiner Boeing⁸, Madlen Schütze⁸, Antonia Trichopoulou^{9,11}, Christina Bamia⁹, Andreas Kyroziis^{11,10}, Carlotta Sacerdote¹², Claudia Agnoli¹³, Domenico Palli¹⁴, Rosario Tumino¹⁵, Amalia Mattiello¹⁶, H. Bas Bueno-de-Mesquita¹⁷, Martine M. Ros^{17,18}, Petra H. M. Peeters¹⁹, Carla H. van Gils¹⁹, Eiliv Lund²⁰, Kjersti Bakken²⁰, Inger T. Gram²⁰, Aurelio Barricarte^{21,22}, Carmen Navarro^{22,23}, Miren Dorronsoro²⁶, Maria José Sánchez^{22,24}, Laudina Rodríguez²⁵, Eric J. Duell²⁷, Göran Hallmans²⁸, Beatrice S. Melin²⁹, Jonas Manjer³⁰, Signe Borgquist³¹, Kay-Tee Khaw³³, Nick Wareham³⁴, Naomi E. Allen³², Konstantinos K. Tsilidis³², Isabelle Romieu³⁵, Sabina Rinaldi³⁵, Paolo Vineis¹, and Elio Riboli¹

Abstract

Background: The etiologies of glioma and meningioma tumors are largely unknown. Although reproductive hormones are thought to influence the risk of these tumors, epidemiologic data are not supportive of this hypothesis; however, few cohort studies have published on this topic. We examined the relation between reproductive factors and the risk of glioma and meningioma among women in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Methods: After a mean of 8.4 years of follow-up, 193 glioma and 194 meningioma cases were identified among 276,212 women. Information on reproductive factors and hormone use was collected at baseline. Cox proportional hazard regression was used to determine hazard ratios (HR) and 95% confidence intervals (95% CI).

Results: No associations were observed between glioma or meningioma risk and reproductive factors, including age at menarche, parity, age at first birth, menopausal status, and age at menopause. A higher risk of meningioma was observed among postmenopausal women who were current users of hormone replacement therapy (HR, 1.79; 95% CI, 1.18-2.71) compared with never users. Similarly, current users of oral contraceptives were at higher risk of meningioma than never users (HR, 3.61; 95% CI, 1.75-7.46).

Conclusion: Our results do not support a role for estrogens and glioma risk. Use of exogenous hormones, especially current use, seems to increase meningioma risk. However, these findings could be due to diagnostic bias and require confirmation.

Impact: Elucidating the role of hormones in brain tumor development has important implications and needs to be further examined using biological measurements. *Cancer Epidemiol Biomarkers Prev*; 19(10); 2562-9. ©2010 AACR.

Authors' Affiliations: ¹Department of Epidemiology and Public Health, Imperial College, London, United Kingdom; ²Brown University, Providence, Rhode Island; ³Unit of Environmental Epidemiology and ⁴Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁵Department of Epidemiology, School of Public Health, Aarhus University, and ⁶Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; ⁷Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; ⁸Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; ⁹WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, and ¹⁰1st Department of Neurology, Eginition Hospital, University of Athens Medical School, and ¹¹Hellenic Health Foundation, Athens, Greece; ¹²Department of Biomedical Science and Human Oncology, CPO-Piemonte, Torino, Italy; ¹³Nutritional Epidemiology Unit, Department of Preventive & Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁴Molecular and Nutritional Epidemiology Unit, ISPO-Cancer Research and Prevention Institute, Florence Italy; ¹⁵Cancer Registry and Histopathology Unit, "Civile-M.P. Arezzo" Hospital, ASP 7 Ragusa, Italy; ¹⁶Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy; ¹⁷National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; ¹⁸Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; ¹⁹Julius Center for Health Sciences and Primary Care, University Medical

Center Utrecht, Utrecht, the Netherlands; ²⁰Department of Community Medicine, University of Tromsø, Tromsø, Norway; ²¹Public Health Institute of Navarra, Pamplona, Spain; ²²CIBER Epidemiología y Salud Pública (CIBERESP), Spain; ²³Department of Epidemiology, Regional Health Authority, Murcia, Spain; ²⁴Andalusian School of Public Health, Granada, Spain; ²⁵Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain; ²⁶Public Health Division of Gipuzkoa, Basque Regional Health Department and CIBERESP, Spain; ²⁷Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Barcelona, Spain; ²⁸Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, and ²⁹Department of Radiation Sciences, Oncology, Umeå University hospital, Umeå, Sweden; Departments of ³⁰Plastic Surgery and ³¹Oncology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden; ³²Cancer Epidemiology Unit, University of Oxford, Nuffield Department of Clinical Medicine, Oxford, United Kingdom; ³³Department of Public Health and Primary Care, University of Cambridge, and ³⁴MRC Epidemiology Unit, Cambridge, United Kingdom; and ³⁵International Agency for Research on Cancer (IARC), Lyon, France

Corresponding Author: Dominique S. Michaud, Brown University, Box G-S121-2, Providence, RI 02912. Phone: 401-863-6365. E-mail: Dominique_Michaud@brown.edu

doi: 10.1158/1055-9965.EPI-10-0447

©2010 American Association for Cancer Research.

Introduction

The etiologies of meningiomas and gliomas, the two most common types of brain tumors, remain largely unknown as established risk factors for many cancers, such as smoking, alcohol, and occupational exposures, do not seem to play a role in these tumors. Established risk factors, including ionizing radiation, family history, certain rare genetic conditions, and a few chromosomal regions (1, 2), can only explain a small portion of total brain tumor cases, leaving the majority of cases with unknown causes. Sex differences in glioma and meningioma incidence suggest that hormones could influence the development of these tumors; the incidence of meningiomas is about 2 times greater in women than in men, whereas the incidence of gliomas is around 1.5 times greater in men than in women (3). Increased growth rates of meningiomas have been observed during pregnancy (4), and a strong association exists between breast cancer and meningioma (5). Taken together, these observations support a role for female hormones in the etiology of meningiomas.

Reproductive factors, including age at menarche, age at first birth, number of pregnancies, and menopausal status, have been examined in relation to meningioma and/or glioma in several case-control studies (6-16) and in three cohort studies (17-20). The majority of findings from these studies are null or inconsistent with respect to direction of association. For meningioma, four studies reported elevated risks with hormone replacement therapy (HRT) use (7, 19, 21, 22). Findings in relation to oral contraceptive use have been mostly null for both glioma and meningioma risk (7, 9-11, 14, 18, 20).

Given that most previous studies on hormonal factors and brain tumors have been case-control studies, and findings are inconsistent, we examined reproductive and exogenous hormone use in relation to risk of glioma and meningioma in a large multicentered prospective cohort study.

Materials and Methods

Study cohort

The European Prospective Investigation into Cancer and Nutrition (EPIC) prospective cohort study was initiated in the early 1990s when 23 centers in 10 European countries collaboratively recruited more than half a million individuals. Additional details on the EPIC study design are reported elsewhere (23).

Loss to follow-up (defined as unknown vital status at the last follow-up time) was <6% across centers. Approval for the study was obtained from the ethical review boards of the participating institutions and from the International Agency for Research on Cancer.

Case ascertainment

Incident cancer cases (including benign brain tumors) were identified through linkage to population cancer

registries in Denmark, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom, or with a combination of methods including linkage to health insurance records, cancer and pathology registries, and active follow-up of study participants or their next of kin in France, Germany, and Greece. We removed France from this analysis due to missing histology on cancer cases. We included all primary incident cases diagnosed with glioma [coded using International Classification of Diseases-Oncology (ICD-O) 2nd edition: 9380-9460, 9505] or meningioma (ICD-O-2 codes 9530-9537) through the end of follow-up (from January 2003 to November 2006 depending on center). Among all women, a total of 193 glioma and 194 meningioma cases were available for analyses on reproductive factors and oral contraceptive use, and 159 glioma and 150 meningioma cases were available for the HRT analyses among perimenopausal and postmenopausal women.

Assessment of HRT, oral contraceptives, and reproductive factors

Information on HRT use, oral contraceptive use, and reproductive factors were collected on the baseline questionnaires. Participants were asked about ever and current use of HRT, age at start and total duration of use, route of administration, and brand name of current HRT use. Analyses were done for ever, current, and former use of HRT, and duration of ever HRT use. Because few cases at baseline were current HRT users (50 meningioma and 34 glioma) we had insufficient power to examine type of HRT. Information on ever use of oral contraceptives, duration of use, and ages at starting and stopping use was collected. Age at menarche and menopause, number of full-term pregnancies (live and still births), age at the first full-term pregnancy, and the reason for menopause (natural versus surgical) were self-reported at recruitment. Information on breastfeeding and its cumulative duration was collected for the first three full-term pregnancies and the last one.

Statistical analysis

We excluded prevalent cancers and benign brain tumors at recruitment (except for nonmelanoma skin cancer) and individuals with incomplete follow-up for this analysis ($n = 27,082$). Only women were included in this analysis. After excluding data from France (missing histologic data on cancer cases), 276,451 women were available for the main analysis.

Menopausal status was defined according to information on menstruation status, ovariectomy, and hysterectomy (for details please refer to Allen et al.; ref. 24). Women were considered perimenopausal if they reported no regular menses over the past 12 months (<9 cycles). Women with missing or incomplete information on the cycle of menses, who reported a hysterectomy, or who indicated use of exogenous hormones while still

menstruating were considered postmenopausal if they were ≥ 55 years old, perimenopausal if they were between 46 and 55 years, or premenopausal if they were < 46 years old at recruitment. For the HRT analyses, we combined perimenopausal women with postmenopausal women because the risk of brain tumors was similar for perimenopausal and postmenopausal women (compared with premenopausal women).

Hazard ratios (HR) and their 95% confidence intervals (95% CI) for brain tumors were estimated using Cox proportional hazards models with age at enrolment as the time scale. Person-time was calculated from date of recruitment until date of incident brain tumor diagnosis, death, date of last contact, or end of follow-up period, whichever came first. All models were stratified by EPIC participating center, to account for center effects related to different recruitment and follow-up procedures, and by age at recruitment in 1-year categories. The proportionality of hazards was verified based on the slope of the Schoenfeld residuals over time, which is equivalent to testing that the log hazard ratio function is constant over time. All models were adjusted (using categorical variables) for smoking status (never, former, current), education (none/primary, technical/professional, secondary, university), and body mass index (BMI; < 25 , ≥ 25 - < 30 , ≥ 30 kg/m²); although these covariates did not appreciably alter the associations, we kept them in the model as these have been previously associated with the risk of brain tumors in one or more studies. Other covariates often adjusted for in cancer analyses were not included in the multivariate models as they are not known or suspected risk factors for brain tumors. Country-specific analyses were also done. All *P* values were two-sided. All analyses were done using SAS 9.1 (SAS Institute Inc.).

Results

After an average of 8.4 years of follow-up, 194 cases of meningioma and 193 cases of glioma were diagnosed among women from nine countries in the EPIC cohort. The average age (SD) at recruitment was 50.4 (10.5) years. The average age (SD) at diagnosis was 53.9 (8.0) years for meningioma and 54.1 (8.9) years for glioma.

Table 1 shows the distribution of exogenous hormone use by country. Oral contraceptive (OC) use was highest in Germany (80.8%) and the Netherlands (72.7%) and lowest in Greece (9.6%). Among postmenopausal and perimenopausal women, HRT use was highest in Germany (55.4%) and lowest in Greece (6.8%).

We examined the relation between potential risk factors (i.e., age, BMI, education, and smoking) and HRT use (Table 2). Women who were current users of HRT at recruitment were younger, slightly leaner, more educated, and more likely to be current smokers than women who were past or never HRT users. In addition, women on HRT were also more likely to have been ever users

of OCs (65% of current HRT users versus 41% of never HRT users).

There was a suggestive increased risk of glioma among postmenopausal and perimenopausal women, compared with premenopausal women, but these associations were not statistically significant (Table 3); the association remained statistically insignificant when perimenopausal and postmenopausal women were combined (HR, 1.68; 95% CI, 0.82-3.41). In contrast, menopausal status seemed to be inversely related to the risk of meningioma (Table 3; combining perimenopausal and postmenopausal, HR, 0.63; 95% CI, 0.34-1.17, compared with premenopausal women). Compared with premenopausal women, women who had a bilateral ovariectomy had a statistically significant elevated risk of glioma (HR, 3.51; 95% CI, 1.45-8.49), and possibly meningioma (as the association was not statistically significant, HR, 1.89; 95% CI, 0.84-4.26; Table 3); these associations did not change when controlling for OC or HRT use. Other reproductive factors, including age at menarche, age at menopause, parity, and age at first birth, were not associated with risk of meningioma or glioma (Table 3). Being ever parous compared with nulliparous was not associated with risk of glioma (HR, 0.96; 95% CI, 0.88-1.04) or meningioma (HR, 1.00; 95% CI, 0.93-1.08). Women who had a hysterectomy (after excluding women who had a bilateral ovariectomy) were at slightly higher risk of meningioma (Table 3). Women with one ovary removed did not have a higher risk of glioma or meningioma (data not shown). Likewise, breastfeeding (ever or by duration) was not related to either type of brain tumors (data not shown).

Women who reported being current users of OCs at the time of recruitment into the cohort had a substantially higher risk of meningioma than women who never used OCs (HR, 3.61; 95% CI, 1.75-7.46), whereas former users did not have an elevated risk (Table 3). This association was very similar among premenopausal women (HR, 3.70; 95% CI, 0.88-15.6; total 40 cases, 3 cases current OC users) and postmenopausal women mutually adjusting for HRT use (HR, 3.54; 95% CI, 1.50-8.37, total 149 cases, 7 cases current OC users; note that current OC users were in the perimenopausal group). There was no clear dose-response with duration of ever OC use and meningioma risk overall (Table 3), but there was a dose-response among premenopausal women [compared with never, HR (95% CI) of 1.21 (0.36-4.06), 1.55 (0.53-4.56), 2.97 (1.08-8.15), 3.22 (1.04-10.0), and 3.60 (1.00-13.0) for ≤ 1 , > 1 - < 5 , ≥ 5 - < 10 , ≥ 10 - ≤ 15 , and > 15 years of use, respectively, *P* trend = 0.01; data not in tables). No association with OC use was observed in relation to glioma risk (Table 3).

Among postmenopausal and perimenopausal women, current users of HRT had a higher risk of meningioma (HR, 1.79; 95% CI, 1.19-2.71) compared with never users, and the risk was also elevated (though not significantly so) among past HRT users (Table 4). There was no clear dose-response relationship between duration of HRT use

Table 1. Use of oral contraceptive at recruitment among all women and menopausal hormone therapy among perimenopausal and postmenopausal women in the EPIC cohort by country

Characteristic	All (n = 276,451)	Denmark (n = 29,320)	Germany (n = 28,481)	Italy (n = 31,519)	Netherlands (n = 27,168)	Norway (n = 35,941)	Spain (n = 25,356)	United Kingdom (n = 56,357)	Greece (n = 15,396)	Sweden (n = 26,913)
Meningioma cases	194	28	15	18	16	43	16	23	4	31
Glioma cases	193	41	12	18	24	12	15	43	4	24
Among all women										
OC ever use (%)										
Yes	55.9	57.6	80.8	40.4	72.7	64.1	42.1	64.9	9.6	38.8
No	40.6	41.3	19.0	58.1	26.7	35.9	57.8	31.9	89.8	36.6
Unknown	3.5	1.1	0.2	1.5	0.6	0	0.1	3.2	0.6	24.7
Nulliparous (%)	12.8	8.8	11.2	10.2	19.8	8.5	9.6	27.6	6.8	7.4
Mean age at first pregnancy (SD), y*	24.8 (4.4)	23.7 (4.2)	24.3 (4.4)	25.8 (4.3)	25.4 (4.2)	24.1 (4.5)	24.6 (3.9)	25.9 (4.7)	24.2 (4.7)	24.7 (4.5)
Mean age at menarche (SD), y	13.1 (1.6)	13.6 (1.6)	13.2 (1.5)	12.5 (1.5)	13.3 (1.6)	13.3 (1.4)	12.9 (1.6)	12.9 (1.6)	13.2 (1.7)	13.5 (1.5)
Hysterectomy (%)	10.2	14.8	15.0	8.9	17.4	4.7	8.4	12.5	8.2	—
Among all postmenopausal or perimenopausal women	n = 174,134	n = 27,209	n = 15,267	n = 19,135	n = 18,157	n = 23,311	n = 11,772	n = 28,977	n = 9,736	n = 20,570
Mean age at menopause (SD), y†	48.7 (4.8)	49.0 (4.9)	49.5 (3.3)	49.0 (4.3)	48.5 (5.1)	47.7 (4.0)	48.0 (4.7)	48.3 (5.5)	47.9 (5.2)	49.2 (4.6)
HRT ever use (%)										
Yes	34.2	46.7	55.4	23.9	26.1	45.3	18.7	38.3	6.8	22.5
No	58.3	51.4	36.3	74.3	72.6	54.7	80.1	56.9	92.7	33.9
Unknown	7.4	1.9	8.3	1.8	1.3	0	1.2	4.9	0.5	43.6
Among ever HRT users	n = 62,092	n = 12,709	n = 8,455	n = 4,583	n = 4,739	n = 10,562	n = 2,195	n = 11,087	n = 662	n = 4,637
Status of use										
Current	66.6	65.5	77.9	44.8	51.5	79.8	55.2	67.8	32.5	63.2
Past	29.1	34.4	22.1	54.4	44.6	8.0	43.8	30.6	67.4	18.5
Unknown	4.3	0.03	0	0.8	3.9	12.2	1.0	1.6	0.1	18.3

*Among parous women.

†Among natural postmenopausal women.

Table 2. Distribution of baseline characteristics by menopausal hormone therapy use among perimenopausal and postmenopausal women and by oral contraceptive use among all women in the EPIC cohort

Characteristic	Menopausal hormone therapy use			Oral contraceptive use		
	Never (n = 101,573)	Former (n = 17,362)	Current (n = 39,711)	Never (n = 112,303)	Former (n = 136,862)	Current (n = 16,223)
Mean age at recruitment (SD), y	57.0 (7.4)	57.4 (5.8)	54.4 (5.3)	54.8 (9.9)	48.7 (8.8)	37.2 (9.2)
Smoking status (%)						
Never	59.0	50.7	47.7	62.8	46.7	54.1
Former	21.7	26.4	28.0	18.8	27.8	23.1
Current	19.3	22.9	24.3	18.5	25.5	22.8
Mean BMI (SD), kg/m ²	26.5 (4.8)	26.3 (4.4)	25.1 (3.9)	26.5 (4.8)	24.9 (4.3)	23.6 (3.8)
Ever use of OCs (%)						
Yes	41.0	53.2	64.6			
No	58.2	46.1	34.6			
Unknown	0.8	0.7	0.8			
Education (%)						
None/Primary	48.8	43.0	33.0	52.7	27.4	12.7
Technical/Professional	24.2	30.5	36.0	20.9	32.0	32.5
Secondary	14.4	13.1	14.7	13.6	18.0	23.0
University	12.6	13.4	16.3	12.8	22.6	31.8
Mean age at menarche (SD), y	13.3 (1.6)	13.2 (1.6)	13.3 (1.6)	13.2 (1.6)	13.1 (1.5)	12.9 (1.5)
Nulliparous (%)	9.3	9.7	7.9	13.1	10.4	37.4
Mean age at first pregnancy (SD), y*	25.0 (4.4)	24.5 (4.3)	24.2 (4.2)	25.0 (4.4)	24.7 (4.5)	24.8 (4.5)
Mean age at menopause (SD), y [†]	48.7 (4.8)	48.2 (5.3)	47.5 (5.5)	48.5 (5.1)	48.4 (4.8)	44.8 (7.7)
Hysterectomy (%)	12.7	19.2	23.1	13.7	11.8	0

NOTE: Values derived by χ^2 and one-way ANOVA or Kruskal-Wallis test; all tests were $P < 0.001$.

*Among parous women.

[†]Among natural postmenopausal women.

and meningioma risk, and no association with HRT use and risk of glioma (Table 4).

Discussion

In this large European prospective cohort study, we observed elevated risks of meningioma among users of OCs or HRT at enrolment when compared with never users. No associations were found for reproductive factors and risk of meningioma. For glioma, we observed no associations with reproductive factors or exogenous hormone use. However, a significantly elevated risk of glioma was observed among women who had undergone a bilateral ovariectomy at baseline, and a statistically non-significant elevated risk was also noted for meningioma tumors; the positive associations were not explained by HRT use. Although the findings for women with bilateral ovariectomy were unexpected and should be interpreted with caution, more studies should examine these to determine if they are of potential significance.

Supporting evidence for a role of hormones in brain tumors comes from a number of case reports of women who experienced rapid changes in symptoms during

pregnancy that were related to the presence of a meningioma (either resulting in a diagnosis or a recurrence of symptoms from an existing tumor; refs. 25-27). Similarly, a study reported growth of a meningioma after estrogen-progestin therapy in a transsexual patient (28). Biological data support an association as well; *in vitro* studies have shown proliferation of meningioma cells with exposure to estradiol or progesterone (29), and inhibition of glioma cell growth with estrogen (30, 31).

To date, studies that have examined reproductive hormones and brain tumors have been largely based on case-control studies. Some of these had small case numbers or relied on proxy-interviews for a portion of the data collected for deceased cases (up to 83% of all cases; ref. 12); moreover, given the low incidence rate of brain tumors, identifying the true source population and representative controls is challenging, and consequently, in these studies, bias is difficult to rule out. Therefore, cohort studies can provide more reliable evidence.

Overall, positive associations between age at menarche and glioma risk have been observed in five studies (four case-control and one cohort; refs. 9, 10, 14, 16, 18), which suggests that delayed puberty may increase subsequent

risk of glioma. In contrast, associations between age at menarche and meningioma have been largely null (6, 8, 10, 11), with one exception where a positive association was reported in a cohort study (19). Other reproductive factors that could influence lifetime hormonal exposure,

such as age at menopause and age at first birth, have not been associated with risk of glioma or meningioma.

Our observation for meningioma risk and HRT was consistent with two prospective cohort studies: the Nurses' Health Study (current versus never users, relative

Table 3. Reproductive factors and risk of meningioma and glioma in the EPIC cohort

	No. of subjects	Meningioma	Meningioma HR (95% CI)*	Glioma	Glioma HR (95% CI)*
Menopausal status					
Premenopausal	102,232	44	1.0	34	1.0
Natural postmenopausal	118,587	99	0.69 (0.35-1.36)	108	1.62 (0.75-3.47)
Perimenopausal	47,170	38	0.57 (0.30-1.11)	37	1.69 (0.81-3.54)
Bilateral oophorectomy	8,029	13	1.89 (0.84-4.26)	14	3.51 (1.45-8.49)
Hysterectomy[†]					
No	209,754	112	1.0	127	1.0
Yes	20,883	21	1.32 (0.81-2.17)	20	1.16 (0.71-1.91)
Missing	37,352	48		32	
Age at menopause (years)[‡]					
<47	25,243	26	1.0	25	1.0
47-53	52,394	41	0.75 (0.45-1.24)	44	0.81 (0.49-1.33)
>53	17,888	13	0.75 (0.38-1.49)	20	1.08 (0.59-1.97)
Missing	70,232	57		56	
Parity					
0	35,341	12	1.0	18	1.0
1	31,409	19	0.97 (0.47-2.02)	21	1.29 (0.67-2.48)
2	81,492	59	1.07 (0.57-2.04)	70	1.58 (0.91-2.76)
≥3	104,215	87	1.40 (0.75-2.59)	73	1.18 (0.68-2.06)
Missing	23,561	17		11	
Age at first full-term pregnancy (years)					
Nulliparous	35,341	12	1.0	18	1.0
<25	115,707	96	1.28 (0.69-2.39)	94	1.49 (0.86-2.58)
≥25-≤30	79,538	57	1.18 (0.62-2.22)	54	1.16 (0.66-2.04)
>30	21,871	12	0.99 (0.44-2.23)	16	1.42 (0.71-2.84)
Missing	23,561	17		11	
Age at menarche (years)					
<12	50,216	36	1.00	36	1.0
≥12-≤15	207,822	140	0.80 (0.54-1.17)	142	0.87 (0.60-1.28)
>15	17,980	18	1.01 (0.55-1.84)	15	0.88 (0.47-1.63)
OC use					
Never	112,105	81	1.0	90	1.0
Former	136,672	92	1.20 (0.86-1.68)	84	0.84 (0.61-1.18)
Current	16,201	10	3.61 (1.75-7.46)	8	1.23 (0.53-2.83)
Missing	11,040	11		11	
Duration of ever OC use (years)					
Never	112,105	81	1.0	90	1.0
≤1	29,804	20	1.10 (0.66-1.83)	16	0.73 (0.42-1.28)
>1-<5	34,657	23	1.19 (0.73-1.95)	17	0.76 (0.44-1.30)
≥5-<10	34,451	28	1.66 (1.05-2.65)	22	1.00 (0.61-1.65)
≥10-≤15	27,742	14	1.01 (0.55-1.87)	18	0.92 (0.53-1.59)
>15	21,277	15	1.54 (0.86-2.77)	13	0.79 (0.43-1.47)
Missing	15,982	13		17	

*Multivariate model includes smoking status, education, BMI, and menopausal status.

[†]Removing women with bilateral ovariectomy.

[‡]Among postmenopausal women (those missing are mostly perimenopausal).

Table 4. Hormone replacement therapy in relation to risk of meningioma and glioma among perimenopausal and postmenopausal women in the EPIC cohort

	No. of subjects	Meningioma	Meningioma MV HR (95% CI)*	Glioma	Glioma MV HR (95% CI)*
HRT use					
Never	101,394	67	1.0	91	1.00
Former	17,324	15	1.40 (0.78-2.49)	18	0.93 (0.55-1.56)
Current	39,617	50	1.79 (1.18-2.71)	34	0.76 (0.49-1.19)
Missing	15,451	18		16	
Duration of ever HRT use (years)					
Never and ≤1	118,360	83	1.0	106	1.00
>1-≤3	12,918	11	1.18 (0.62-2.25)	12	0.91 (0.49-1.68)
>3-≤5	8,499	14	2.32 (1.28-4.20)	8	0.93 (0.44-1.94)
>5-≤10	9,678	8	1.09 (0.51-2.32)	5	0.36 (0.13-0.98)
>10	4,239	6	1.34 (0.55-3.30)	6	0.89 (0.37-2.14)
Missing	20,092	28		22	

Abbreviation: MV, multivariate.

*Adjusting for smoking status, education, surgical/natural/perimenopause, oral contraceptive use, and BMI.

risk (RR, 1.86; 95% CI, 1.07-3.24; 66 meningioma postmenopausal cases; ref. 19) and the Million Women Study (current versus never, RR, 1.34; 95% CI, 1.03-1.75; ref. 22), and with two retrospective studies (comparing ever to never HRT use, OR, 1.7; 95% CI, 1.0-2.8; ref. 7; and OR, 2.2; 95% CI, 1.9-2.6; ref. 21). However, three other case-control studies found no associations with HRT and meningioma (6, 10, 11). The association among former users was not as strong in our dataset (Table 4), suggesting that the effect, if causal, is likely to act late in the stages of carcinogenesis. However, it is unclear how hormones are involved in brain tumors from a mechanistic standpoint.

Results from earlier studies on oral contraceptive use and risk of meningiomas are less consistent with our findings, as most of the earlier studies reported null associations (7, 10, 19, 20) and one association was inverse (6). However, few of the previous studies reported results for current use of OC; one case-control with data on current use observed a RR of 2.5 (95% CI, 0.5-12.6; ref. 11), whereas two other reported small increased risk with large confidence intervals due to small case numbers for current OC use (RR, 1.34; 95% CI, 0.18-9.96; ref. 19; and RR, 1.33; 95% CI, 0.43-4.12; ref. 10). Therefore, it is possible that an association was missed in some studies if most users were past users and if the effect is only present among current users (as observed with HRT use). It is conceivable that the mechanism involves increased tumor growth rates during the exposure period (current use) and that the risk decreases with time after no longer being a current user. The statistically significant dose-response relationship for duration of OC use (among ever users) observed among premenopausal women (at baseline) supports this hypothesis; more research is needed to examine this finding.

Alternatively, the increase in risk of meningioma among active exogenous hormone users could be due

to diagnostic bias; conceivably, women under prescription drugs who are under more rigorous or more frequent medical surveillance may be more likely to have a follow-up of symptoms that could lead to the diagnosis of benign meningioma. In this cohort, age-specific rates were comparable with those in the United States (which are comparable with European rates; ref. 32). In this cohort, the age-specific rates for glioma were 4.2 (per 100,000) for ages 35 to 44 and 11.5 for ages 65 to 74, and 2.9 and 11.5 for meningiomas in those same age groups, respectively. In the Central Brain Tumor Registry of the United States report (which separates benign and malignant tumors), the age-specific rates range from 4.4 at ages 35 to 44, to 17.3 for ages 65 to 74 for glioma, and from 2.9 to 14.2 for the same age comparisons for meningioma. Therefore, case ascertainment seems to be as expected in this cohort for both subtypes of brain tumors.

The strengths of this cohort study include a prospective design, which removes potential error from selection bias or use of proxy interviews, and detailed data on reproductive factors, exogenous hormone use, and other variables that could be potential confounders. The weaknesses of this study include having no followed data on HRT use, and the change in HRT, OC, and/or menopausal status among some women during follow-up, which will cause misclassification of exposure and potentially bias the results. However, as this would result in nondifferential misclassification, it would most likely result in bias towards the null. Moreover, we had insufficient brain tumor cases to examine duration of exogenous hormone use with sufficient power, or to explore analyses with different hormone combinations. Our findings need to be confirmed in other populations.

In this study, we observed an elevated risk of meningioma among current users of HRT or OC. In contrast, other reproductive factors were not associated with

the risk of meningioma. Furthermore, no relation was observed for reproductive factors and the risk of glioma. Additional studies should carefully examine the relation with current use of exogenous hormones, both HRT and OC, and meningioma risk.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society in Denmark; Ligue contre le Cancer, Société 3M, Mutuelle Générale de l'Éducation Nationale, and Institut National de la Santé et de la Recherche Médicale in France; Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research in Germany; Ministry of Health

and Social Solidarity, Stavros Niarchos Foundation, and Hellenic Health Foundation in Greece; Italian Association for Research on Cancer (AIRC) and National Research Council in Italy; Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), and World Cancer Research Fund (WCRF) in the Netherlands; Statistics Netherlands; Norwegian Cancer Society in Norway; Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and ISCIII RETIC (RD06/0020) in Spain; Swedish Cancer Society, Swedish Scientific Council, and the Regional Government of Skåne and Västerbotten in Sweden; Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust in the United Kingdom.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 04/27/2010; revised 07/08/2010; accepted 07/09/2010; published online 10/07/2010.

References

- Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. *Nat Genet* 2009;41:905–8.
- Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. *Nat Genet* 2009;41:899–904.
- CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States; 2005.
- Koper JW, Lamberts SW. Meningiomas, epidermal growth factor and progesterone. *Hum Reprod* 1994;9 Suppl 1:190–4.
- Rao G, Giordano SH, Liu J, McCutcheon IE. The association of breast cancer and meningioma in men and women. *Neurosurgery* 2009;65:483–9.
- Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. *Int J Cancer* 2006;119:1152–7.
- Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M. Risk of brain tumors associated with exposure to exogenous female sex hormones. *Am J Epidemiol* 2006;164:629–36.
- Wigertz A, Lonn S, Hall P, et al. Reproductive factors and risk of meningioma and glioma. *Cancer Epidemiol Biomarkers Prev* 2008;17:2663–70.
- Huang K, Whelan EA, Ruder AM, et al. Reproductive factors and risk of glioma in women. *Cancer Epidemiol Biomarkers Prev* 2004;13:1583–8.
- Hatch EE, Linet MS, Zhang J, et al. Reproductive and hormonal factors and risk of brain tumors in adult females. *Int J Cancer* 2005;114:797–805.
- Custer B, Longstreth WT, Jr., Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. *BMC Cancer* 2006;6:152.
- Cantor KP, Lynch CF, Johnson D. Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). *Cancer Causes Control* 1993;4:505–11.
- Cicuttini FM, Hurley SF, Forbes A, et al. Association of adult glioma with medical conditions, family and reproductive history. *Int J Cancer* 1997;71:203–7.
- Hochberg F, Toniolo P, Cole P, Salzman M. Nonoccupational risk indicators of glioblastoma in adults. *J Neurooncol* 1990;8:55–60.
- Schlehofer B, Blettner M, Wahrendorf J. Association between brain tumors and menopausal status. *J Natl Cancer Inst* 1992;84:1346–9.
- Felini MJ, Olshan AF, Schroeder JC, et al. Reproductive factors and hormone use and risk of adult gliomas. *Cancer Causes Control* 2009;20:87–96.
- Lambe M, Coogan P, Baron J. Reproductive factors and the risk of brain tumors: a population-based study in Sweden. *Int J Cancer* 1997;72:389–93.
- Silvera SA, Miller AB, Rohan TE. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. *Int J Cancer* 2006;118:1321–4.
- Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. *J Neurosurg* 2003;99:848–53.
- Benson VS, Pirie K, Green J, Casabonne D, Beral V. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. *Br J Cancer* 2008;99:185–90.
- Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? *J Clin Oncol* 2008;26:279–82.
- Benson VS, Pirie K, Green J, et al. Hormone replacement therapy and incidence of central nervous system tumours in the million women study. *Int J Cancer* 2010;127:1692–8.
- Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* 2002;5:1113–24.
- Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer* 2008;15:485–97.
- Saitoh Y, Oku Y, Izumoto S, Go J. Rapid growth of a meningioma during pregnancy: relationship with estrogen and progesterone receptors—case report. *Neurol Med Chir (Tokyo)* 1989;29:440–3.
- Wan WL, Geller JL, Feldon SE, Sadun AA. Visual loss caused by rapidly progressive intracranial meningiomas during pregnancy. *Ophthalmology* 1990;97:18–21.
- Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. *J Neurol Neurosurg Psychiatry* 1958;21:89–91.
- Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. *N Engl J Med* 2007;357:2411–2.
- Jay JR, MacLaughlin DT, Riley KR, Martuza RL. Modulation of meningioma cell growth by sex steroid hormones *in vitro*. *J Neurosurg* 1985;62:757–62.
- Kang SH, Cho HT, Devi S, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. *Cancer Res* 2006;66:11991–7.
- Lis A, Ciesielski MJ, Barone TA, Scott BE, Fenstermaker RA, Plunkett RJ. 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, *in vitro*. *Cancer Lett* 2004;213:57–65.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. Lyon, France: IARC Press; 2010.